Polycyclo Ring System Having The Thiazole Ring As One Of The Cyclos Patents (Class 514/373)
  • Patent number: 10603321
    Abstract: A method of treating HIV in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having a general Formula 1, or a pharmaceutically acceptable salt or ester thereof: wherein R1 is selected from H, optionally-substituted aryl, optionally-substituted heteroaryl, or optionally-substituted aliphatic; each R2 is independently selected from H, halogen, cyano, thioether, oxo, optionally-substituted amino, optionally-substituted heteroaryl, optionally-substituted aryl, or optionally-substituted aliphatic; a is 3 to 7; and the ring designates a heterocyclic or heteroaryl structure.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: March 31, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Thomas E. Smithgall
  • Patent number: 10111862
    Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: October 30, 2018
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: John Clifford Chabala, Thomas A. Jordan, Ke-Qing Ling, John G. Gleason, William A. Kinney
  • Patent number: 9808001
    Abstract: A synergistic microbicidal composition having two components. The first component is a nonionic surfactant with structure: R2O(CH2CH(CH3)O)3(CH2CH2O)5H, where R2 is a mixture of C8-C14 linear alkyl groups. The second component is 2-bromo-2-nitropropane-1,3-diol. The weight ratio of the nonionic surfactant to 2-bromo-2-nitropropane-1,3-diol is from 1:0.08 to 1:0.12 or 1:0.2 to 1:1.8286.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: November 7, 2017
    Assignees: ROHM AND HAAS COMPANY, DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Usha Gandhi, Christine McInnis, Kiran Pareek, Paul O. Schook, Nigel G. Watson, Terry Michael Williams, Bei Yin
  • Patent number: 9801919
    Abstract: An oral composition contains an enhanced antibacterial effective amount of an antioxidant and an extract of Magnolia.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: October 31, 2017
    Assignee: WM. WRIGLEY JR. COMPANY
    Inventors: Minmin Tian, Michael W. Dodds, Michael J. Greenberg
  • Patent number: 9428472
    Abstract: Methods of treating, preventing and ameliorating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives are disclosed. Pharmaceutical compositions containing 1,2-benzisothiazolinone and isoindolinone derivatives are useful for treating bacterial infections caused by drug resistant strains of bacteria, including but not limited to methicillin and vancomycin bacterial organisms.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: August 30, 2016
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Deepu Alex, Richard Calderone, Stephen Peters
  • Patent number: 9382572
    Abstract: Disclosed are methods of determining biocide efficacy using flow cytometry. The methods can be used to determine the synergy between at least two biocides.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: July 5, 2016
    Assignee: Ecolab USA Inc.
    Inventors: Timothy J. Tidwell, Zachary Richard Broussard
  • Patent number: 9133142
    Abstract: A salt or cocrystal of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol (component a) and at least one acid component (b1) or at least one acid component (b2), wherein the salt or cocrystal of component (a) and component (b2) is present in crystalline and/or amorphous form, a pharmaceutical composition comprising said salt or cocrystal, and a method of treating pain in a subject in need thereof by administering an effective amount of said salt or cocrystal.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: September 15, 2015
    Assignee: Gruenenthal GmbH
    Inventors: Michael Gruss, Magda Kraszewski
  • Patent number: 9089129
    Abstract: A non-aerosol, foaming high alcohol content hand sanitizer is provided which has excellent antimicrobial activity and tolerance for organic load and excellent residual activity, as well as enhanced moisturization and skin-feel properties over currently marketed alcohol-based sanitizers. The inventive composition achieves an unexpectedly large amount of quality, stable foam even in the presence of significant quantities of skin conditioning agents through the use of novel silicone surfactants and achieves enhanced and prolonged antimicrobial efficacy through the combination of high alcohol content and activity enhancing components.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: July 28, 2015
    Assignee: AMERICAN STERILIZER COMPANY
    Inventors: Christopher C. Heisig, Nancy-Hope E. Kaiser
  • Publication number: 20150133442
    Abstract: The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 14, 2015
    Inventors: Kun Ping Lu, Matthew Brian Boxer, Mindy Irene Emily Davis, Rajan Pragani, Min Shen, Anton Momtchilov Simeonov, Shuo Wei, Xiao Zhen Zhou
  • Publication number: 20150132405
    Abstract: The present invention provides synergistic combinations of monochlorourea with other biocides for controlling microbial growth in aqueous systems. It also provides synergistic combinations of dimethyl monochlorourea with other biocides for controlling growth in aqueous systems. The synergistic combinations of monochlorourea and dimethyl monochlorourea with other biocides allows for the reduced use of total biocides to provide control of microbial growth in aqueous systems.
    Type: Application
    Filed: March 14, 2014
    Publication date: May 14, 2015
    Applicant: HERCULES INCORPORATED
    Inventor: John S Chapman
  • Publication number: 20150126479
    Abstract: What is described herein is an environment-friendly, highly aqueous solution of 1,2-benzisothiazolin-3-one (BIT) which is free from volatile organic compounds (VOC's), glycols, derivatives of glycols, glycerols and/or derivatives of glycerols. The composition comprises: (i) about 0.1% to about 30% by wt. of BIT; (ii) about 5% to about 15% by wt. of neutralizing agent; (iii) about 50% to about 85% by wt. of water; and (iv) about 0.1% to about 5% by wt. of chelating agent. The aqueous solution of BIT may further comprise at least one water soluble form of a co-biocide. The composition is efficient in protecting aqueous media against microbial attack in various industrial applications.
    Type: Application
    Filed: May 9, 2012
    Publication date: May 7, 2015
    Applicant: ISP Investments Inc.
    Inventors: Raman Premachandran, Karen Winkowski, Najeeb H. Hakimi
  • Publication number: 20150119428
    Abstract: Mew tranilast complexes and new tranilast cocrystals are disclosed. These include all tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-amtnoben2oic acid complex, a 1:1 tranilast 4-am!nobers2oic acid cocrystal, a 1:1 tranilast 2,4-di?hydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed.
    Type: Application
    Filed: March 29, 2013
    Publication date: April 30, 2015
    Inventors: Joanne Holland, Christopher Frampton
  • Patent number: 9012445
    Abstract: In one aspect, the invention relates to substituted 4-(1H-pyrazol-4-yl)benzyl analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: January 12, 2013
    Date of Patent: April 21, 2015
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Michael R. Wood, Bruce J. Melancon, Michael S. Poslusney, James C. Tarr
  • Publication number: 20150051256
    Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Naomi Kitamoto
  • Publication number: 20150031685
    Abstract: The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (?) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
    Type: Application
    Filed: March 5, 2013
    Publication date: January 29, 2015
    Applicant: Dr. Reeddy's Laboratories Ltd.
    Inventors: Pradip Kumar Sasmal, Chintakunta Vamseekrishna, Vijay Potluri, Ashok Tehim, Yonghua Gai, Hang Zhang
  • Patent number: 8940778
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: January 27, 2015
    Assignee: AbbVie Inc.
    Inventors: Yujia Dai, Steven K Davidsen, Anna M. Ericsson, Kresna Hartandi, Zhiqin Ji, Michael R. Michaelides
  • Patent number: 8940779
    Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: January 27, 2015
    Assignee: Rohm and Haas Company
    Inventors: John W. Ashmore, Beverly J. El A'mma, Beat Heer, Kiran Pareek
  • Patent number: 8921427
    Abstract: An antiseptic preparation is provided for the production of wound dressings or bandages. The preparation includes at least one alginate and at least one antiseptically active substance selected from the group biguanide derivatives, octenidine and taurolidine. Processes for the production of the antiseptic preparations, and the use thereof, are also provided.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: December 30, 2014
    Assignee: Lohmann & Rauscher GmbH & Co. KG
    Inventors: Christian Rohrer, Helmut Leuprecht, Corneliu Iulian Alupei
  • Patent number: 8921404
    Abstract: The invention relates to azole derivatives of the general formula I as defined in the present application as well as to their uses in treatment of conditions that would benefit from their inhibitory effect on hormone sensitive lipase, HSL, an allosteric enzyme in adipocytes which is inhibited by insulin and is responsible for the breakdown of fats in fat cells and thus for transferring fat constituents into the blood stream. Inhibition of this enzyme is therefore equivalent to an insulin-like effect of the compounds of the invention.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: December 30, 2014
    Assignee: Sanofi
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Muller, Hubert Heuer, Norbert Tennagels
  • Patent number: 8912186
    Abstract: The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: December 16, 2014
    Assignee: Universitaet des Saarlandes
    Inventors: Matthias Engel, Wolfgang Fröhner, Adriane Stroba, Ricardo M. Biondi
  • Patent number: 8901158
    Abstract: The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol mono-phosphatase (IMPase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bi-polar disorder, the compounds having a structure of Formula (I), or is a pharmaceutically acceptable salt thereof; Formula (I); in which: E is S or Se and each of phenyl rings A and B is optionally substituted with one or more substituents, in which each substituent is selected independently from: (1) a halogen, which is preferably selected from F, Cl and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: December 2, 2014
    Assignee: Isis Innovation Ltd.
    Inventors: Grant C. Churchill, Sridhar R. Vasudevan, Nisha Singh
  • Patent number: 8901170
    Abstract: Compounds of formula (I) wherein the symbols have the meaning given in the specification, as well as processes for preparing the compounds (I), pesticidal compositions and synergistic mixtures comprising compounds (I), methods for the control of insects, acarids or nematodes by contacting the pests or their food supply, habitat or breeding grounds with a pesticidally effective amount of compounds formula (I), and a method for treating, controlling, preventing or protecting animals against infestation or infection by parasites which comprises orally, topically or parenterally administering or applying to the animals a parasiticidally effective amount of compounds of formula (I).
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: December 2, 2014
    Assignee: BASF SE
    Inventors: Matthias Pohlman, Michael Hofmann, Henricus Maria Martinus Bastiaans, Michael Rack, Deborah L. Culbertson, Hassan Oloumi-Sadeghi, Takeo Hokama, Christopher Palmer
  • Patent number: 8895594
    Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: November 25, 2014
    Assignee: Rohm and Haas Company
    Inventors: John W. Ashmore, Beverly J. El A'mma, Beat Heer, Kiran Pareek
  • Patent number: 8895595
    Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: November 25, 2014
    Assignee: Rohm and Haas Company
    Inventors: John W. Ashmore, Beverly J. El A'mma, Beat Heer, Kiran Pareek
  • Patent number: 8895593
    Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: November 25, 2014
    Assignee: Rohm and Haas Company
    Inventors: John W. Ashmore, Beverly J. El A'mma, Beat Heer, Kiran Pareek
  • Publication number: 20140336184
    Abstract: The present invention concerns methods and compositions regarding suppression of double stranded RNA-activated protein kinase (PKR) to enhance cognition in an individual. In specific cases, an inhibitor of PKR is provided to the individual such that cognition is enhanced thereby, including by enhancing memory, for example. Kits are encompassed in certain embodiments.
    Type: Application
    Filed: November 29, 2012
    Publication date: November 13, 2014
    Inventors: Mauro Costa-Mattioli, Ping Jun Zhu, Jeremy A. May
  • Patent number: 8877755
    Abstract: The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: November 4, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventor: Timothy J. Barberich
  • Publication number: 20140296310
    Abstract: Methods of treating, preventing and ameliorating bacteria! infections with 1,2-benzisothiazolinone and isoindolinone derivatives are disclosed. Pharmaceutical compositions containing 1,2-benzisothiazolinone and isoindolinone derivatives are useful for treating bacteria! infections caused by drug resistant strains of bacteria, including but not limited to methicillin and vancomycin bacterial organisms.
    Type: Application
    Filed: August 16, 2012
    Publication date: October 2, 2014
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Deepu Alex, Richard Calderone, Stephen Peters
  • Patent number: 8846732
    Abstract: Biogenic sulfide production is synergistically inhibited by treating sulfate-reducing bacteria (SRB) with a biocide and a metabolic inhibitor. The biocide directly kills a first portion of the SRB. The metabolic inhibitor inhibits sulfate-reducing growth of a second portion of the SRB without directly killing the second portion of the SRB. The treatment of SRB with both a biocide and a metabolic inhibitor provides effective biogenic sulfide inhibition at significantly lower concentrations than would be required if the biocide or metabolic inhibitor was used alone.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: September 30, 2014
    Assignees: ConocoPhillips Company, University Technologies International, Inc.
    Inventors: Gary E. Jenneman, Anne Greene, Gerrit Voordouw
  • Publication number: 20140288084
    Abstract: In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: October 28, 2012
    Publication date: September 25, 2014
    Applicant: VANDERBILT UNIVERSITY
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Michael R. Woods, Corey R. Hopkins, Bruce J. Melancon, Michael S. Poslusney, Darren W. Engers
  • Patent number: 8841462
    Abstract: The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: September 23, 2014
    Inventors: Robert A. Heald, Philip Jackson, Joseph P. Lyssikatos, Stephen Price, Pascal Pierre Alexandre Savy
  • Patent number: 8835475
    Abstract: The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: September 16, 2014
    Assignee: AbbVie Inc.
    Inventors: William A. Carroll, Michael J. Dart, Teodozyj Kolasa, Tongmei Li, Derek W. Nelson, Meena Patel, Sridhar Peddi, Arturo Perez-Medrano, Xueqing Wang
  • Publication number: 20140206676
    Abstract: In one aspect, the invention relates to substituted 4-(1H-pyrazol-4-yl)benzyl analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: January 12, 2013
    Publication date: July 24, 2014
    Applicant: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Michael R. Wood, Bruce J. Melancon, Michael S. Poslusney, James C. Tarr
  • Patent number: 8785490
    Abstract: Some embodiments of this invention include methods for treating disease and methods for administering a compound of Formula (I). In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of Formula (I). Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I).
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: July 22, 2014
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: John O. Trent, Jason B. Meier, Kelby B. Napier
  • Patent number: 8772322
    Abstract: A preservative composition comprising: (a) 1,2-Benzisothiazolin-3-one (BIT); (b) 3-Iodo-2-propynyl carbamate (IPBC); and (c) a mixture of 5-Chloro-2-methyl-4-isothiazolin-3-one (CMIT) and 2-Methyl-4-isothiazolm-3-one (MIT).
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: July 8, 2014
    Assignee: ISP Investments Inc.
    Inventors: Gilles Pradier, Alain Girault, Willem Anker, Christophe Amyot
  • Patent number: 8765657
    Abstract: The invention relates to a microbicidal use solution which comprises a) one or more isothiazolin-3-ones and b) one or two organic amines selected from N-dodecylpropane-1,3-diamine and bis(aminopropyl)-dodecylamine and optionally c) one or more oxidizing agents. The use solution is preferably in the form of technical and domestic products.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: July 1, 2014
    Assignee: L'Air Liquide, Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude
    Inventors: Wolfgang Beilfuss, Ralf Gradtke, Ingo Krull, Jennifer Knopf
  • Patent number: 8765806
    Abstract: Provided is a biocidal composition comprising 2,6-dimethyl-m-dioxane-4-ol acetate and an isothiazolinone biocidal compound. The composition is useful for controlling microorganisms in aqueous or water containing systems.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: July 1, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Ioana Annis, Jon B. Raymond, Emerentiana Sianawati
  • Patent number: 8741940
    Abstract: Synergistic microbicidal compositions containing N-(n-butyl)-1,2-benzisothiazolin-3-one or N-methyl-1,2-benzisothiazolin-3-one.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: June 3, 2014
    Assignee: Rohm and Haas Company
    Inventors: Richard Levy, Megan Anne Diehl, Dolores Ann Shaw, Eileen Fleck Warwick
  • Publication number: 20140135215
    Abstract: A compound of the formula I where W, X and Y are for example each CH; R1 is H; R2 is halogen; and R6 is, for formula I, for example, OH, CN, C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C6-alkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alkenyloxy, C2-C6-alkynyl, C2-C6-haloalkynyl, C2-C6-alkynyloxy, optionally substituted C1 to C3-alkyl, or optionally substituted C1-C6-alkoxy, or R6 is, for formula II, for example, CN, C3-C8-cycloalkyl, or optionally substituted C3-C6-alkyl; and/or salts thereof; and their use as pesticidal agents.
    Type: Application
    Filed: December 17, 2013
    Publication date: May 15, 2014
    Applicant: Syngenta Crop Protection LLC
    Inventors: Ottmar Franz HUETER, Peter RENOLD, Werner ZAMBACH, Thomas PITTERNA, Peter MAIENFISCH
  • Patent number: 8722713
    Abstract: A synergistic antimicrobial composition containing 1,2-benzisothiazolin-3-one and tris(hydroxymethyl)nitromethane.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: May 13, 2014
    Assignee: Dow Global Technologies LLC
    Inventor: Bei Yin
  • Publication number: 20140128440
    Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 8, 2014
    Inventors: John W. Ashmore, Beverly J. El A'mma, Beat Heer, Kiran Pareek
  • Publication number: 20140121251
    Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 1, 2014
    Inventors: John W. Ashmore, Beverly J. El A'mma, Beat Heer, Kiran Pareek
  • Publication number: 20140121253
    Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 1, 2014
    Inventors: John W. Ashmore, Beverly J. El A'mma, Beat Heer, Kiran Pareek
  • Publication number: 20140121252
    Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 1, 2014
    Inventors: John W. Ashmore, Beverly J. El A'mma, Beat Heer, Kiran Pareek
  • Patent number: 8697754
    Abstract: Biocidal compositions and their use in aqueous media, such as metalworking fluids, the compositions comprising a biocidal agent; and a non-biocidal primary amino alcohol compound of the formula (I): wherein R1, R2, R3, R4, and R5 are as defined herein.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: April 15, 2014
    Inventors: Patrick E. Brutto, Charles E. Coburn, G. David Green, Bonnie A. Pyzowski, Raymond J. Swedo, John Pohlman
  • Publication number: 20140100253
    Abstract: A synergistic antimicrobial composition containing 1,2-benzisothiazolin-3-one and tris(hydroxymethyl)nitromethane.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Inventor: Bei Yin
  • Publication number: 20140094449
    Abstract: The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol mono-phosphatase (IMPase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bi-polar disorder, the compounds having a structure of Formula (I), or is a pharmaceutically acceptable salt thereof; Formula (I); in which: E is S or Se and each of phenyl rings A and B is optionally substituted with one or more substituents, in which each substituent is selected independently from: (1) a halogen, which is preferably selected from F, Cl and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br.
    Type: Application
    Filed: January 18, 2012
    Publication date: April 3, 2014
    Applicant: ISIS INNOVATION LTD.
    Inventors: Grant C. Churchill, Sridhar R. Vasudevan, Nisha Singh
  • Patent number: 8680128
    Abstract: A synergistic antimicrobial composition containing 1,2-benzisothiazolin-3-one and tris(hydroxymethyl)nitromethane.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: March 25, 2014
    Assignee: Dow Global Technologies LLC
    Inventor: Bei Yin
  • Patent number: 8658679
    Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: February 25, 2014
    Assignee: Rohm and Haas Company
    Inventors: John William Ashmore, Beverly Jean El A'mma, Beat Heer, Kiran Pareek
  • Publication number: 20140024688
    Abstract: The present technology relates to biocidal compositions and methods that contain and utilize at least one biocidal agent and at least one potentiator system wherein the resultant combination has an enhanced biocidal efficacy. The present technology also discloses a rapid screening assay for determining biocidal compositions with enhanced efficacy, e.g., a microbial contact kill time of 5 minutes or less. Further, the present technology provides a method of determining biocidally effective concentrations of biocidal compositions comprising at least one biocidal agent and at least one potentiator system.
    Type: Application
    Filed: September 20, 2013
    Publication date: January 23, 2014
    Applicant: STEPAN COMPANY
    Inventors: Molly Ryan Callahan, David Shelton